Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

Hello. At this time, I would like to welcome everyone to the Exact Sciences. Third quarter, 2024 earnings conference call. (Operator Instructions) I would now like to turn the call over to Erik ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on EXAS stock, giving a Buy rating yesterday. Puneet Souda’s ...

Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

Exact Sciences Q3 EPS loss of $0.21 fell short of analyst expectations. 2024 revenue guidance lowered amid screening segment ...

Exact Sciences Corporation EXAS reported a net loss of 21 cents in third-quarter 2024 compared with break-even earnings in the year-ago quarter. The figure was wider than the Zacks Consensus ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

Exact Sciences reports quarterly GAAP losses of 21 cents per share, which missed the analyst consensus estimate for losses of 20 cents. Quarterly sales of $709 million miss the consensus estimate ...

Exact Sciences' Q3 earnings report has led to a ~25% drop in its share price, due to a slight guidance cut and narrow revenue miss. Despite impressive historic revenue growth, Exact faces ...

Exact Sciences Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook.